Provision of Clinical Trial Monitoring to the FaR-RMS Trial
What the buyer wrote
The FaR-RMS trial The University of Birmingham Cancer Research Clinical Trials Unit are working on a collaboration with a large Pharmaceutical company to add a new arm to an existing study. The trial is a multicentre, randomised phase II trial evaluating the new therapy against a control arm in paediatric patients with relapsed/refractory rhabdomyosarcoma. Patients will receive therapy for up to 12 cycles (approx. 12 months) and will be followed-up for 5 years.
Details
- What the buyer calls it
- Provision of Clinical Trial Monitoring to the FaR-RMS Trial
- How they are buying
- Advertised, open to anyoneAny supplier could bid without being invited first.
- Type
- services
- Where
- in the West Midlands
Who the buyer named
Peter Nobbs was the named contact on this notice.